We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
B-North is creating an SME business bank that will deliver fast decisions with loans being given in two weeks. Its model is formed around strong relationships with both brokers and customers. B-North is in a positive conversation with the British Business Bank for Tier 2 debt, and its FinTech enabled lending platform is excellent. The funds will be used to expand the team and develop the platform. The company also aims at assembling a highly-experienced and ambitious management team supported by a heavyweight board.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £2,815,350
Patch is a modern plant shop for contemporary plant people. It helps in finding the most suitable plants and delivering them to the door. The company has delivered over 2,50,000 plants to over 82,000 customers in Paris and London. Patch has witnessed solid growth at +124% vs last year, reaching £4.48m in revenue. The company has a 4.6-star rating on TrustPilot and, it has been featured in The Times, The Telegraph etc. The funds will be used to expand across Europe, eliminate the middle-man and expand into the B2B market.

Pitch Rated

68%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £2,412,150
TimeToTrade is an online trading platform which gives every investor access to advanced trading technologies. TimeToTrade aims to make investing easier. They currently have 31,000 registered users that are making over 500,000 trading signals every month.
days to go: Expired investment: £146,480
A digital solution helping individuals get ahead by learning new life skills that hiring businesses are looking for. QDOOZ is helping those that are looking to build character qualities and skills that employers are seeking to bring into their business. The company will provide their services via an app, which will consist of videos, infographics and articles to assist members in improving themselves and succeeding in the interview process. QDOOZ is aiming to partner with multiple Chartered Professional Membership organisations across the UK. This will potentially result in an initial audience of 1.5m users when launching the product. Furthermore, QDOOZ is also seeking to bring their services to 1.5m university students by arranging discussions with UCAS Media. Their monetisation strategy involves a monthly or annual premium membership that will offer additional content with no advertisements. A freemium membership will also be offered and QDOOZ will generate revenue via advertisements.
days to go: Expired investment: £575,225
Actve is on a mission to build a platform that caters to the new wave of instructors, social media influencers and athletes becoming online content creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £166,670
Charm is a peer-to-peer impact investment platform that allows a user to use his/her investments to drive positive change in the world while earning a financial return. Morgan Stanley estimates that 85% of people are interested in sustainable investing. Charm enables individuals to fund projects led by high-impact entrepreneurs selling clean energy solutions in developing economies. Users can view their investments on the company's transparent, personalised impact investment dashboard, as well as, earn social, environmental and financial bottom line returns for their contributions. The company secured a £496,000 grant funding to develop its platform, refine its offering & provide growth capital. It is in the process of becoming an appointed representative of a Financial Conduct Authority (FCA) authorised entity post this funding round. It will use the investment to expand its team, develop its platform, and raise brand awareness.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £273,720
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph